Preclinical development contract facilities that support the NIH CounterACT research network and other interested investigators. The studies are performed at no cost to the Investigator and the Investigator retains Intellectual Property and primary rights to developed data. A purpose of these programs is to generate data in support of research applications to the CounterACT peer-reviewed grant program. See below for more detailed information on each program as well as application materials.
- CounterACT Efficacy Research Facility (CERF)(pdf, 449 KB) (pdf, 439 kb)
Pilot studies to demonstrate efficacy of candidate compounds
- CounterACT Preclinical Development Facility (CPDF)(pdf, 383 KB) (pdf, 375 kb)
Pilot non-GLP Preclinical Safety, Toxicity, and Pharmacodynamics/Pharmacokinetics (PD/PK) studies to facilitate characterization and optimization of hits early in the development process. Preliminary evidence of compound efficacy is required.
- CounterACT Neurotherapeutics Screening (CNS) Program(pdf, 1030 KB) (pdf, 1 mb)
In vivo screening for anti-seizure and/or neuroprotective efficacy of compounds against OP chemical threat agents.
CounterACT Ocular Therapeutics Screening (COTS) Program(pdf, 460 KB) (pdf, 449 kb)
Conduct pilot studies to evaluate efficacy of compounds against the acute and/or chronic effects of eye exposure to sulfur mustard.